Off-the-shelf CAR-T therapy has moved another step toward a decisive test in leukaemia. Cellectis is enrolling a pivotal Phase 2 study of lasme-cel, a gene-edited donor-cell treatment for people with relapsed or refractory B-cell acute lymphoblastic leukaemia, or B-ALL.
Early results presented in June 2026 were encouraging, but they came from very small groups in a Phase 1 trial. The central question is now whether an allogeneic product—made in advance from donor cells—can reproduce those responses in a larger, more representative population with acceptable safety.
How off-the-shelf CAR-T differs from personalised CAR-T
Most approved CAR-T therapies start with a patient’s own T cells. The cells are collected, genetically modified to recognise a cancer target, expanded and then returned to that patient. This personalised manufacturing can produce powerful responses, but it takes time and may be difficult when a patient is very ill or has poor-quality T cells.
An allogeneic, off-the-shelf CAR-T product starts with cells from a healthy donor. Manufacturers can edit and expand a batch in advance, freeze individual doses and ship them when needed. In principle, this approach could shorten waiting times and make production more consistent.
The trade-off is biological complexity. Donor T cells can recognise a patient’s tissues as foreign, while the patient’s immune system can reject the infused cells. Developers therefore edit genes to reduce these conflicts and use lymphodepleting medicines to create a temporary window in which the engineered cells can expand.
What lasme-cel is designed to do
Lasme-cel is a gene-edited allogeneic CAR-T therapy directed against CD22, a protein found on many B-ALL cells. The programme is being studied in BALLI-01, registered as NCT04150497, for patients whose disease has returned or has not responded to previous treatment.
Targeting CD22 may be useful after therapies directed at another B-cell marker, CD19. Some leukaemias relapse by losing or reducing CD19, leaving fewer targets for a CD19 CAR-T cell to recognise. A CD22-directed therapy offers a different route, although cancer can also evolve around that pressure.
What the Phase 1 results showed
According to final Phase 1 results released by Cellectis at the 2026 European Hematology Association congress, 45 heavily pretreated patients received lasme-cel. Fifteen were treated at the recommended Phase 2 dose, while seven met the narrower target-population definition now being used for the pivotal study.
In that seven-person subgroup, all seven had an overall response, and four achieved complete remission or complete remission with incomplete blood-count recovery. The company reported that three of those four complete responders were negative for measurable residual disease. All seven subsequently proceeded to a haematopoietic stem-cell transplant.
Those numbers are promising, especially in people who had received a median of five previous treatment lines. They are not conclusive. A result from seven selected participants can change substantially when a study expands, and proceeding to transplant makes it harder to separate the longer-term contribution of each treatment.
Lasme-cel safety: CAR-T reactions and donor-cell risks
CAR-T treatment can trigger cytokine release syndrome, a systemic inflammatory reaction, and immune effector cell-associated neurotoxicity syndrome, or ICANS. Cellectis reported grade 3 or worse cytokine release syndrome in 4% of the 45 treated participants, grade 3 or worse ICANS in 4%, and a severe immune-effector-cell-associated haemophagocytic syndrome-like event in 2%. The company said all of these events resolved.
Larger studies will be needed to estimate uncommon risks more reliably. Investigators must also monitor infection, prolonged low blood counts, graft-versus-host disease and whether the patient’s immune system clears the donor cells too quickly for a lasting effect.
Why the pivotal Phase 2 study matters
The Phase 2 portion of BALLI-01 is intended to support a potential regulatory submission. Cellectis has said the first interim analysis is expected in the fourth quarter of 2026. In June, the US Food and Drug Administration granted lasme-cel Regenerative Medicine Advanced Therapy designation, a programme that can increase interaction with the agency for qualifying candidates. The FDA explains that RMAT designation is a development pathway; it is not approval and does not establish effectiveness.
The pivotal trial should provide a clearer response rate, a better picture of durability and more reliable safety estimates. It will also test whether centres can deliver the supporting lymphodepletion regimen consistently and whether a ready-made product produces a meaningful logistical advantage.
A platform test, not a cure announcement
Lasme-cel is important beyond one product because it tests the broader off-the-shelf CAR-T model. If donor-derived cells can be manufactured at scale, delivered quickly and controlled safely, the approach could widen access to engineered cell therapy. But a pivotal trial underway is not the same as a successful trial, and remission is not synonymous with cure.
The next evidence to watch is the larger Phase 2 dataset: how many patients respond, how deep those responses are, how long they last, what role subsequent transplant plays and whether safety remains manageable. Until those data arrive, the most accurate description is promising but preliminary.
Sources and further reading
- Cellectis: final Phase 1 BALLI-01 results presented at EHA 2026
- ClinicalTrials.gov: BALLI-01, NCT04150497
- US FDA: Regenerative Medicine Advanced Therapy designation
Reporting note: Cellectis develops lasme-cel, and the efficacy and safety figures above come from a company release describing a scientific-congress presentation. FutureTechDose covers biotechnology progress for a general audience. This article is informational and does not provide medical or investment advice.
Leave a Reply